Antibody drug conjugate manufacturing

Antibody drug conjugates (ADCs) are emerging therapeutic agents that chemically combine a monoclonal antibody to a cytotoxic drug, most often used to treat cancer in a more targeted way than traditional chemotherapy. Here, ADC experts share why these advancements are exciting for the pharma industry, the benefits of this new therapeutic approach, the key challenges in manufacturing, and their hopes for the future of the space.